Revance Therapeutics, Inc.
RVNC · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.69 | 0.05 | 0.32 | 0.06 |
| FCF Yield | -7.61% | -15.58% | -15.56% | -5.62% |
| EV / EBITDA | -33.73 | -22.29 | -18.38 | -23.18 |
| Quality | ||||
| ROIC | -7.57% | -7.57% | -10.78% | -13.27% |
| Gross Margin | 70.55% | 70.85% | 67.48% | 72.94% |
| Cash Conversion Ratio | 0.98 | 1.10 | 1.33 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | 31.51% | 34.91% | 38.15% | 44.36% |
| Free Cash Flow Growth | 1.07% | 38.51% | -51.99% | 19.75% |
| Safety | ||||
| Net Debt / EBITDA | -14.84 | -13.50 | -8.10 | -6.97 |
| Interest Coverage | -4.79 | -6.09 | -8.76 | -9.84 |
| Efficiency | ||||
| Inventory Turnover | 0.21 | 0.28 | 0.34 | 0.41 |
| Cash Conversion Cycle | 444.51 | 348.52 | 291.57 | 187.04 |